Kitmap, a new online directory and database of scientific infrastructure and equipment owned by publicly funded institutes, has been launched today.
It’s part of a wider project by the Ministry for Business to get better use of the country’s science and technology research infrastructure and includes 260 R&D items owned by Crown Research Institutes, the National eScience Infrastructure, and Callaghan Innovation.
Advanced facilities now accessible include clean rooms, Good Manufacturing Practice-certified testing, pilot and manufacturing infrastructure, and specialised nuclear magnetic resonance (NMR) spectroscopy capabilities.
The platform, hosted by Callaghan, will soon add generative AI functionality to suggest potential methods and machinery required for rapid prototyping of new products or innovation, said Callaghan CEO Stefan Korn.
The Coalition Government is no longer subsidising EVs through the clean car discount scheme, but it is now going to subsidise low emissions heavy vehicles.
Climate Change Minister Simon Watts and Energy Minister Simeon Brown have announced a $27.75 million low emissions heavy vehicle fund. It will pay up to 25% of the cost of new zero and low-emissions heavy vehicles.
They said high upfront costs and the unknown total cost of ownership were barriers to the uptake of zero and low-emissions heavy vehicles.
“Transport accounts for 18% of New Zealand’s total emissions, which is why the Government wants to remove barriers and accelerate businesses to switch to lower-emissions technologies,” Watts said.
NZX-listed Blis Technologies has entered a trading halt.
The probiotic manufacturer requested a trading halt after becoming aware of a patent filing that could potentially significantly affect the company.
In a notice to NZ RegCo, the company said it needed time to assess those impacts, including obtaining legal advice.
Blis requested the trading halt be implemented for two days, and reported an announcement on the implications of that patent would trigger the end of it.
In a separate note to the market, NZRegCo approved the application.
Last month, Blis reported that revenue for the first quarter ending June 30 of $3.4m was up from $600,000 year on year.
It also noted Blis would invest $500,000 during FY25 to ensure continued access to the China market, after recent changes in the scientific classification of its strains required new regulatory approvals to be sought.
For FY25 Blis forecasted double-digit revenue growth, and a similar ebitda to the $800,000 reported in FY24.